Thus, according to our data, PARPi-resistant cancers with PARG downregulation could be targeted by ARH3 inhibitors, further highlighting the need for ARH3 inhibitor development (Drown et al., 2018; Rack et al., 2018). This evidence concerns the gene ADPRS and cancer.